{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:36:59Z","timestamp":1769510219871,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11940-016-0408-3","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T02:13:17Z","timestamp":1460686397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Update on New Daily Persistent Headache"],"prefix":"10.1007","volume":"18","author":[{"given":"Hida","family":"Nierenburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence C.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"issue":"6","key":"408_CR1","first-page":"317","volume":"26","author":"WJ Vanast","year":"1981","unstructured":"Vanast WJ, Edmonton MD. Program abstracts of the twenty-eighth annual meeting the american association for the study of headache june 27, 28 and 29, 1986, chicago, illinois U.S.A. new daily persistent headaches definition of a benign syndrome. Headache. 1981;26(6):317.","journal-title":"Headache"},{"issue":"7","key":"408_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11916-014-0431-6","volume":"18","author":"T Rozen","year":"2014","unstructured":"Rozen T. New daily persistent headache: an update. Curr Pain Headache Rep. 2014;18(7):431. This article provides the most recent review of definition, pathophysiology and treatments for NDPH. Dr. Rozen has published several articles on this condition but this is to our knowledge his most recent one.","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"408_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1526-4610.2011.01871.x","volume":"51","author":"T Rozen","year":"2011","unstructured":"Rozen T. New daily persistent headache: clinical perspective. Headache. 2011;51(4):641\u20139.","journal-title":"Headache"},{"issue":"9","key":"408_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version): 4.10 new daily persistent headache. Cephalalgia. 2013;33(9):679. Most recent classification of headache disorders. This article provides diagnostic criteria for all headache disorders (both primary and secondary). It is a good reference for any clinician to refer to when evaluating patients with headache.","journal-title":"Cephalalgia"},{"issue":"S1","key":"408_CR5","first-page":"52","volume":"24","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2004","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 2nd edition: 4.8 new daily persistent headache. Cephalalgia. 2004;24(S1):52.","journal-title":"Cephalalgia"},{"issue":"17","key":"408_CR6","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1212\/WNL.0b013e3181dad5de","volume":"74","author":"MS Robbins","year":"2010","unstructured":"Robbins MS, Grosberg BM, Napchan U, Crystal SC, Lipton RB. Clinical and prognostic subforms of new daily-persistent headache. Neurology. 2010;74(17):1358. Also a good source for understanding description, etiology, pathophysiology and treatments for NDPH. Given that it was published in 2010, NDPH diagnostic criteria used is from ICHD-2 (has some differences from ICHD-3) but goes into good detail on different proposed sub-forms of NDPH.","journal-title":"Neurology"},{"issue":"7","key":"408_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1526-4610.2006.00722.x","volume":"47","author":"T Rozen","year":"2007","unstructured":"Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor \u03b1 levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007;47(7):1050.","journal-title":"Headache"},{"issue":"6","key":"408_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1526-4610.2005.05143_2.x","volume":"45","author":"T Rozen","year":"2005","unstructured":"Rozen T, Roth JM, Denenberg N. Saturday poster presentations\u20142: joint hypermobility as a predisposing factor for the development of new daily persistent headache. Headache. 2005;45(6):823.","journal-title":"Headache"},{"issue":"2","key":"408_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11910-013-0425-5","volume":"14","author":"SG Joshi","year":"2014","unstructured":"Joshi SG, Mathew PG, Markley HG. New daily persistent headache and potential new therapeutic agents. Curr Neurol Neurosci Rep. 2014;14(2):425.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"S1","key":"408_CR10","first-page":"S49","volume":"48","author":"T Rozen","year":"2008","unstructured":"Rozen T. Special issue: 50th Annual Scientific Meeting of the American Headache Society Abstracts. S24: doxycycline for new daily persistent headache. Headache. 2008;48(S1):S49.","journal-title":"Headache"},{"key":"408_CR11","unstructured":"Truven health analytics. Micromedex solutions. Retrieved 12\/28, 2015, from https:\/\/www.micromedexsolutions.com\/home\/dispatch\/ssl\/true 2015."},{"issue":"4","key":"408_CR12","first-page":"389","volume":"42","author":"T Rozen","year":"2002","unstructured":"Rozen T. 44th Annual Scientific Meeting, American Scientific Society, June 21\u201323, 2002, Seattle, Washington (pages 389\u2013463). S133: successful treatment of new daily persistent headache with gabapentin and topiramate. Headache. 2002;42(4):389.","journal-title":"Headache"},{"issue":"1","key":"408_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10194-009-0171-x","volume":"11","author":"S Prakash","year":"2010","unstructured":"Prakash S, Shah ND. Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain. 2010;11(1):59.","journal-title":"J Headache Pain"},{"issue":"10","key":"408_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1526-4610.2008.01234.x","volume":"48","author":"MJ Marmura","year":"2008","unstructured":"Marmura MJ, Passero FC, Young WB. Mexiletine for refractory chronic daily headache: a report of nine cases. Headache. 2008;48(10):1506.","journal-title":"Headache"},{"issue":"7","key":"408_CR15","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1526-4610.2008.01192.x","volume":"48","author":"WB Young","year":"2008","unstructured":"Young WB, Marmura M, Ashkenazi A, Evans RW. Expert opinion: greater occipital nerve and other anesthetic injections for primary headache disorders. Headache. 2008;48(7):1122.","journal-title":"Headache"},{"issue":"3","key":"408_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/head.12053","volume":"53","author":"A Blumenfeld","year":"2013","unstructured":"Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches\u2014a narrative review. Headache. 2013;53(3):437. Excellent source to learn how to perform nerve blocks. Standarized method for performing nerve blockade presented. Has good pictures showing technique for nerve blockade.","journal-title":"Headache"},{"issue":"6","key":"408_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10194-008-0078-y","volume":"9","author":"RC Spears","year":"2008","unstructured":"Spears RC. Efficacy of botulinum toxin type A in new daily persistent headache. J Headache Pain. 2008;9(6):405.","journal-title":"J Headache Pain"},{"issue":"9","key":"408_CR18","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406. Describes onabotulinum toxin paradigm for chronic migraine. Goes into detail on mixing toxin, units used per muscle. Has good pictures on injection locations and amount of toxin injected per site. Similar paradigm is being used in NDPH studies.","journal-title":"Headache"},{"issue":"7","key":"408_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804.","journal-title":"Cephalalgia"},{"issue":"7","key":"408_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793.","journal-title":"Cephalalgia"},{"issue":"1","key":"408_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11916-009-0010-4","volume":"13","author":"KJ Mack","year":"2009","unstructured":"Mack KJ. New daily persistent headache in children and adults. Curr Pain Headache Rep. 2009;13(1):47.","journal-title":"Curr Pain Headache Rep"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-016-0408-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0408-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:01:25Z","timestamp":1659096085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-016-0408-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0408-3","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]},"assertion":[{"value":"15 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Hida Nierenburg declares no conflict of interest. Lawrence C. Newman is an advisor for and received honorarium from Allergan, Lilly, and Teva. He receives royalties from Oxford Univ Press and Springer Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"25"}}